Uranyl photoprobing of conformational changes in DNA induced by drug binding

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Uranyl photoprobing of conformational changes in DNA induced by drug binding. / Nielsen, Peter E.; Møllegaard, N E; Jeppesen, C.

I: Anti-Cancer Drug Design, Bind 5, Nr. 1, 02.1990, s. 105-10.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Nielsen, PE, Møllegaard, NE & Jeppesen, C 1990, 'Uranyl photoprobing of conformational changes in DNA induced by drug binding', Anti-Cancer Drug Design, bind 5, nr. 1, s. 105-10.

APA

Nielsen, P. E., Møllegaard, N. E., & Jeppesen, C. (1990). Uranyl photoprobing of conformational changes in DNA induced by drug binding. Anti-Cancer Drug Design, 5(1), 105-10.

Vancouver

Nielsen PE, Møllegaard NE, Jeppesen C. Uranyl photoprobing of conformational changes in DNA induced by drug binding. Anti-Cancer Drug Design. 1990 feb.;5(1):105-10.

Author

Nielsen, Peter E. ; Møllegaard, N E ; Jeppesen, C. / Uranyl photoprobing of conformational changes in DNA induced by drug binding. I: Anti-Cancer Drug Design. 1990 ; Bind 5, Nr. 1. s. 105-10.

Bibtex

@article{20b28417573d4a5199aade9f50a93e73,
title = "Uranyl photoprobing of conformational changes in DNA induced by drug binding",
abstract = "The effect on DNA conformation upon binding of the bis-intercalator, N,N'-diacridinyl spermidine is studied by uranyl mediated DNA photocleavage and gel retardation. It is shown that a characteristic A-tract correlated 10 base pair modulation of the uranyl photocleavage of bent (kinetoplast) DNA is suppressed upon binding of the diacridine. Likewise, the anomalous slow gel electrophoretic migration of bent-DNA is abolished by diacridine binding. At higher diacridine/DNA ratios a DNA conformation in which G-residues become hypersensitive to uranyl photocleavage is induced.",
keywords = "DNA/analysis, DNA Probes/pharmacology, DNA, Circular/analysis, DNA, Kinetoplast, Electrophoresis, Polyacrylamide Gel, In Vitro Techniques, Nucleic Acid Conformation/drug effects, Photochemistry",
author = "Nielsen, {Peter E.} and M{\o}llegaard, {N E} and C Jeppesen",
year = "1990",
month = feb,
language = "English",
volume = "5",
pages = "105--10",
journal = "Anti-Cancer Drug Design",
issn = "0266-9536",
publisher = "Cognizant Communication Corporation",
number = "1",

}

RIS

TY - JOUR

T1 - Uranyl photoprobing of conformational changes in DNA induced by drug binding

AU - Nielsen, Peter E.

AU - Møllegaard, N E

AU - Jeppesen, C

PY - 1990/2

Y1 - 1990/2

N2 - The effect on DNA conformation upon binding of the bis-intercalator, N,N'-diacridinyl spermidine is studied by uranyl mediated DNA photocleavage and gel retardation. It is shown that a characteristic A-tract correlated 10 base pair modulation of the uranyl photocleavage of bent (kinetoplast) DNA is suppressed upon binding of the diacridine. Likewise, the anomalous slow gel electrophoretic migration of bent-DNA is abolished by diacridine binding. At higher diacridine/DNA ratios a DNA conformation in which G-residues become hypersensitive to uranyl photocleavage is induced.

AB - The effect on DNA conformation upon binding of the bis-intercalator, N,N'-diacridinyl spermidine is studied by uranyl mediated DNA photocleavage and gel retardation. It is shown that a characteristic A-tract correlated 10 base pair modulation of the uranyl photocleavage of bent (kinetoplast) DNA is suppressed upon binding of the diacridine. Likewise, the anomalous slow gel electrophoretic migration of bent-DNA is abolished by diacridine binding. At higher diacridine/DNA ratios a DNA conformation in which G-residues become hypersensitive to uranyl photocleavage is induced.

KW - DNA/analysis

KW - DNA Probes/pharmacology

KW - DNA, Circular/analysis

KW - DNA, Kinetoplast

KW - Electrophoresis, Polyacrylamide Gel

KW - In Vitro Techniques

KW - Nucleic Acid Conformation/drug effects

KW - Photochemistry

M3 - Journal article

C2 - 2156513

VL - 5

SP - 105

EP - 110

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

SN - 0266-9536

IS - 1

ER -

ID: 203632167